FindTrial
Sign In

A new method and clinical prognosis of prostate cancer biological target segmentation based on artificial intelligence and multimodal radiomics: a study based on medical records

A new method for hierarchical engraving of prostate cancer biological targets and clinical prognosis based on artificial intelligence and multimodal radiomics

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055401
Enrollment
Unknown
Registered
2022-01-08
Start date
2022-02-01
Completion date
Unknown
Last updated
2023-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

case series:none

Sponsors

Sichuan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Pathologically confirmed prostate adenocarcinoma by systematic + targeted biopsy before treatment; 2. Patients with clinical limited stage who received radiotherapy for the first time, with complete medical records; 3. Accept PET-CT (18F-FDG, 11C-CHO, PSMAPET-CT), MRI, CT and other multimodal imaging examinations before radiotherapy; 4. Aged = 70 points, no serious comorbidities or complications; 5. MRI and CT imaging examination after radiotherapy; 6. Gene detection data of pathological specimens.

Exclusion criteria

Exclusion criteria: 1. Those with a history of pelvic radiotherapy; 2. Those with lymph node metastasis or distant metastasis; 3. Those who have undergone prostatectomy or who do not have radiotherapy indications.

Design outcomes

Primary

MeasureTime frame
prostate-specific antigen from serum;BRCA1/2 gene;—

Countries

China

Contacts

Public ContactWang Jie

Sichuan Cancer Hospital

wxr792000@163.com+86 18908178720

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026